PER-100-03Completed未知
RANDOMIZED STUDY OF COADYUVANT CHEMOTHERAPY WITH STANDARD REGIMES OF CYCLOPHOSPHAMIDE, METHOTREXATE AND FLUORURACILO - (CMF) OR DOXORUBICINE AND CICLOFOSFAMIDA - (AC) VERSUS CAPECITABINE IN WOMEN 65 YEARS OF AGE OR MORE POSITIVE OR NEGATIVE NODULES WITH HIGH-RISK BREAST CANCER.
EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG),0 sites0 target enrollmentStarted: February 6, 2004Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 0 to 0 (—)
Inclusion Criteria
- •Patients with operable, histologically confirmad adenocarcinoma of the female breast.
- •STNM Stage: T1-3, N1. MO or T2, NO, MO if a primary lesion > 3 cm.
- •or T3. NO. MO
- •Age 65 years or older
- •Performance status 0-2 (Common Toxicity Criteria).
Exclusion Criteria
- Not provided
Investigators
Similar Trials
Recruiting
Not Applicable
Randomized study of neoadjvant chemotherapy with FAP versus DCF in patients with resectable Esophageal cancerJPRN-UMIN000004555Department of Gastroenterologial Surgery, Graduate School of Medicine,Osaka University160
Not yet recruiting
Phase 2
A STUDY OF CHEMOTHERAPY FOLLOWED BY RADIOTHERAPY IN BORDERLINE RESECTABLE PANCREATIC CANCER(BRPC) AND LOCALLY ADVANCED PANCREATIC CANCER (LAPC)CTRI/2021/10/037538PGIMER CHANDIGARH
Completed
Phase 2
A phase II study of combination chemotherapy with carboplatin plus S-1 in advanced lung squamous cell carcinomaung cancerJPRN-UMIN000006983Hamamatsu University School of Medicine50
Completed
Phase 2
A phase II study of combination chemotherapy with carboplatin plus S-1 in advanced and recurrence non small cell lung cancernon-small-cell lung cancerJPRN-UMIN000010189ational Hospital Organization Osaka20
Completed
Phase 2
A Phase II study of combination chemotherapy with TS-1 and Trastuzumab for patients with HER2 positive advanced or recurrent gastric cancer.advanced or recurrent gastric cancerJPRN-UMIN000008220Osaka medical center for cancer and cardiovascular diseases20